Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Accumulated Expenses: 2014-2025

Historic Accumulated Expenses for RedHill Biopharma (RDHL) over the last 7 years, with Jun 2025 value amounting to $693,000.

  • RedHill Biopharma's Accumulated Expenses rose 209.83% to $693,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $693,000, marking a year-over-year increase of 209.83%. This contributed to the annual value of $10.0 million for FY2024, which is 117.62% up from last year.
  • According to the latest figures from Q2 2025, RedHill Biopharma's Accumulated Expenses is $693,000, which was down 93.07% from $10.0 million recorded in Q4 2024.
  • RedHill Biopharma's Accumulated Expenses' 5-year high stood at $20.9 million during Q4 2021, with a 5-year trough of -$10.5 million in Q2 2023.
  • In the last 3 years, RedHill Biopharma's Accumulated Expenses had a median value of $2.6 million in 2023 and averaged $3.5 million.
  • The largest annual percentage gain for RedHill Biopharma's Accumulated Expenses in the last 5 years was 426.14% (2023), contrasted with its biggest fall of 1,441.67% (2023).
  • Over the past 5 years, RedHill Biopharma's Accumulated Expenses (Quarterly) stood at $20.9 million in 2021, then declined by 14.10% to $17.9 million in 2022, then crashed by 74.42% to $4.6 million in 2023, then spiked by 117.62% to $10.0 million in 2024, then spiked by 209.83% to $693,000 in 2025.
  • Its last three reported values are $693,000 in Q2 2025, $10.0 million for Q4 2024, and -$631,000 during Q2 2024.